Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Functional Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Months to 23 Months
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more

Conditions: Healthy Volunteer
Interventions: ABBV-1354; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Cypress, California • Grayslake, Illinois

Conditions: Ulcerative Colitis
Interventions: ABBV-668; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Chula Vista, California • Maitland, Florida • Margate, Florida + 13 more

Conditions: Parkinson Disease
Interventions: Tavapadon; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Acute Ischemic Stroke
Interventions: Elezanumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years to 90 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Phoenix, Arizona • Long Beach, California • Washington D.C., District of Columbia + 18 more

Conditions: Episodic Migraine, Chronic Migraine
Interventions: Atogepant 60 mg; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 42
States / cities: Phoenix, Arizona • Fresno, California • Los Alamitos, California + 35 more

Conditions: Psoriatic Arthritis
Interventions: Lutikizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 16
States / cities: Huntington Beach, California • Avon Park, Florida • Clearwater, Florida + 13 more

Conditions: Migraine
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Unresectable Metastatic Colorectal Cancer
Interventions: ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 15 more

Conditions: Seizures
Interventions: CVL-865; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants

A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Open-label Trial in Parkinson's Disease (PD)

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

About this AbbVie sponsor directory page